Efficacité au long terme de la toxine botulique dans l’hyperactivité de vessie chez les patients atteints de sclérose en plaques

Compston, 2002, Multiple sclerosis, Lancet Lond Engl, 359, 1221, 10.1016/S0140-6736(02)08220-X Rubin, 2013, Management of multiple sclerosis: an overview, Dis--Mon DM, 59, 253, 10.1016/j.disamonth.2013.03.012 Sand, 2013, The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients, Dis--Mon DM, 59, 261, 10.1016/j.disamonth.2013.03.013 Zecca, 2016, Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients’ quality of life, Eur J Neurol, 23, 1228, 10.1111/ene.13010 de Sèze, 2007, GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines, Mult Scler Houndmills Basingstoke Engl, 13, 915, 10.1177/1352458506075651 Stöhrer, 2009, EAU guidelines on neurogenic lower urinary tract dysfunction, Eur Urol, 56, 81, 10.1016/j.eururo.2009.04.028 Phé, 2016, Management of neurogenic bladder in patients with multiple sclerosis, Nat Rev Urol, 13, 275, 10.1038/nrurol.2016.53 Gamé, 2008, Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections, Eur Urol, 53, 613, 10.1016/j.eururo.2007.08.039 Sadiq, 2015, Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients, Curr Urol Rep, 16, 44, 10.1007/s11934-015-0519-5 Mouttalib, 2010, Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment, BJU Int, 106, 1677, 10.1111/j.1464-410X.2010.09435.x Ginsberg, 2012, Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity, J Urol, 187, 2131, 10.1016/j.juro.2012.01.125 Cruz, 2011, Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial, Eur Urol, 60, 742, 10.1016/j.eururo.2011.07.002 Kennelly, 2015, Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study, Neurourol Urodyn, 36, 368, 10.1002/nau.22934 Rovner, 2013, OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity, Neurourol Urodyn, 32, 1109, 10.1002/nau.22376 Khan, 2011, Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis, J Urol, 185, 1344, 10.1016/j.juro.2010.12.002 de Sèze, 2011, Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: Results of a multicenter prospective study, Neurourol Urodynam, 30, 306, 10.1002/nau.20958 Giannantoni, 2009, Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results, Eur Urol, 55, 705, 10.1016/j.eururo.2008.08.048 Kalsi, 2007, Botulinum injections for the treatment of bladder symptoms of multiple sclerosis, Ann Neurol, 62, 452, 10.1002/ana.21209 Jabbari, 2008, Botulinum toxin A: a new treatment option for multiple-sclerosis-related bladder overactivity?, Nat Clin Pract Neurol, 4, 188, 10.1038/ncpneuro0749 Deffontaines-Rufin, 2011, Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients, Int Braz J Urol, 37, 642, 10.1590/S1677-55382011000500012 Schulte-Baukloh, 2006, Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis, Neurourol Urodyn, 25, 110, 10.1002/nau.20153 Chartier-Kastler, 2016, Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity, Neurourol Urodyn, 35, 595, 10.1002/nau.22757 Schurch, 2007, Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence, Arch Phys Med Rehabil, 88, 646, 10.1016/j.apmr.2007.02.009